Equillium Inc., of La Jolla, Calif., said it plans to develop EQ-001 for the treatment of lupus nephritis. Equillium remains on track to initiate the Equate phase Ib/II trial in acute graft-vs.-host disease in the first quarter of 2019. A proof-of-concept trial will start in severe asthma in the second quarter of 2019.